|MDACC Study No:||2012-0984 (clinicaltrials.gov NCT No: NCT01660906)|
|Title:||A Phase IV, Open-Label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients with Chronic Low-Grade Non-Hematologic Toxicity to Imatinib|
|Principal Investigator:||Jorge Cortes|
|Study Description:||The goal of this clinical research study is to learn if switching to dasatinib |
from imatinib can help to improve the side effects that you had while receiving
imatinib. The safety of this drug will also be studied.
Dasatinib is designed to block certain proteins from causing cancer cells to
grow out of control. This may cause the cancer cells to die.